AbstractThe Carpentier‐Edwards supra‐annular porcine bioprosthesis was implanted in 1,576 operations (1,536 patients with 1,704 valves) between 1981 and 1987. The mean age of the patients was 61.9 years (range 13 to 87 years). During the years 1981 and 1987, approximately 90 of the total valvular surgery population received the prosthesis. The early mortality was 7.0 (included patients with concomitant procedures including coronary artery bypass and ascending aortic aneurysm resection). Late mortality was 4.0 per patient‐year. The total cumulative follow‐up was 4,237 years. Thromboembolism (TE) was 2.4 per patient‐year (fatal 0.4 per patient‐year) (minor 1.2; major 1.3); antithromboembolic therapy‐related hemorrhage (ATH) 0.5 (fatal 0.07); prosthetic valve endocarditis (PVE) 0.5 (fatal 0.2); periprosthetic leak (PPL) 0.3 (fatal 0); clinical valve dysfunction (CVD) 0.3 (fatal 0.02); and structural valve deterioration/primary tissue failure (SVD) 0.2/patient‐year (fatal 0). Thromboembolism and structural valve deterioration were the significant complications, SVD occurring primarily between the fourth and fifth year of evaluation. The overall patient survival was 77.1± 1.4 at five years. The patients were classified as 89.6 NYHA functional Class III and IV preoperatively and 96.1 Class I and II postoperatively. The freedom at five years from TE was 90.6± 1.0; SVD 98.9± 0.5; and reoperation 95.9± 0.9. Freedom from all valve‐related complications at five years was 84.1± 1.3; valve‐related mortality 96.8± 0.7; mortality and reoperation (valve failure) 92.9± 1.1; mortality and residual morbidity (treatment failure) 93.7± 0.9; and mortality, residual morbidity, and reoperation (valve failure and dysfunction) 90.0± 1.2. There were 28 valve‐related deaths of a total 280 deaths (early 4, late 24) (TE 17; ATH 3; CVD 1; PVE 7; PPL 0; and SVD 0). Valve‐related reoperations were performed in 32 patients (TE 2; CVD 4; PVE 7; PPL 11; and SVD 8). The supra‐annular Carpentier‐Edwards porcine bioprosthesis has provided very satisfactory clinical performance and afforded patients an excellent quality of life. The long‐term durability of this low pressure glutaraldehyde fixed prosthesis will be determined by observa
展开▼
